APOMAB

Pharmaceutical products and preparations of antibodies, immunoreactive and/or antigen-binding fragments of antibodies, or direct modifications, conjugates or functionalized derivatives of antibodies, for health care, all the foregoing for the treatment of malignant, inflammatory and autoimmune disorders and conditions, tissue trauma and tissue ischaemia; pharmaceutical products and preparations of antibodies, immunoreactive and/or antigen-binding fragments of antibodies, or direct modifications, conjugates or functionalized derivatives of antibodies, for radio-immuno-diagnosis or radio-immuno-therapy, the foregoing for the diagnosis and treatment of malignant, inflammatory and autoimmune disorders and conditions, tissue trauma and tissue ischaemia; pharmaceutical preparations used in the therapy and diagnosis of malignant, inflammatory and autoimmune disorders and conditions, tissue trauma and tissue ischaemia; diagnostic preparations for detecting the presence of malignant, inflammatory and autoimmune disorders and conditions, tissue trauma and tissue ischaemia in humans, the foregoing for medical use; monoclonal antibodies and fragments thereof for cancer research and pharmaceutical development, biomedical research, [ veterinary vaccines, ]veterinary diagnostic and treatment purposes, clinical trials for cancer pharmaceuticals, cancer diagnosis and cancer therapy purposes; cultures and preparations of hybridoma and other cells for medical, diagnostic and veterinary purposes; medicinal products of antibodies, immunoreactive and/or antigen-binding fragments of antibodies, or direct modifications, conjugates or functionalized derivatives of antibodies, the foregoing for the treatment of malignant, inflammatory and autoimmune disorders and conditions, tissue trauma and tissue ischaemia